Emapalumab Therapy for Hemophagocytic Lymphohistiocytosis Before Reduced-Intensity Transplantation Improves Chimerism

Research Report on Pre-HCT Emapalumab Therapy Improving Donor Chimerism in Children with HLH Background and Objective of the Study Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune disorder caused by pathological immune activation. The primary mechanism involves the functional deficiency of cytotoxic activity in natural killer (...